var data={"title":"Bupivacaine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bupivacaine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5766?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bupivacaine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bupivacaine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=bupivacaine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Bupivacaine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708636\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Obstetrical anesthesia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The bupivacaine 0.75% concentration is not recommended for obstetrical anesthesia. There have been reports of cardiac arrest with difficult resuscitation or death during use of bupivacaine for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% concentration should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142923\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bupivacaine Spinal;</li>\n      <li>Marcaine;</li>\n      <li>Marcaine Preservative Free;</li>\n      <li>Marcaine Spinal;</li>\n      <li>P-Care M;</li>\n      <li>ReadySharp Bupivacaine;</li>\n      <li>Sensorcaine;</li>\n      <li>Sensorcaine-MPF;</li>\n      <li>Sensorcaine-MPF Spinal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142924\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Marcaine;</li>\n      <li>Sensorcaine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142962\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Local Anesthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142927\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient. Do not use solutions containing preservatives for caudal or epidural block. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Local anesthesia: Infiltration:</b> 0.25% infiltrated locally; maximum: 175 mg. <b>Note:</b> Aspiration should be performed prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (Mulroy 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Caudal block</b>  (preservative free): 15 to 30 <b>mL</b> of 0.25% or 0.5% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Epidural block</b> (other than caudal block; preservative free): Administer in 3 to 5<b> mL</b> increments, allowing sufficient time to detect toxic manifestations of inadvertent IV or intrathecal administration: 10 to 20 <b>mL</b> of 0.25% or 0.5% </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Surgical procedures requiring a high degree of muscle relaxation and prolonged effects <b>only</b>: 10 to 20 <b>mL</b> of 0.75% (<b>Note:</b> Not to be used in obstetrical cases) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral nerve block:</b> 5 <b>mL</b> of 0.25% or 0.5%; maximum: 400 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sympathetic nerve block:</b> 20 to 50 <b>mL</b> of 0.25% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Retrobulbar anesthesia:</b> 2 to 4 <b>mL</b> of 0.75% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Spinal anesthesia:</b> Preservative free solution of 0.75% bupivacaine in 8.25% dextrose:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lower extremity and perineal procedures: 1 <b>mL</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lower abdominal procedures: 1.6 <b>mL</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Normal vaginal delivery: 0.8 <b>mL</b> (higher doses may be required in some patients) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cesarean delivery: 1 to 1.4 <b>mL</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Combined spinal-epidural (CSE) technique for labor analgesia (off-label dosing [spinal component]): </b> 1.75 to 2.5 mg combined with fentanyl 15 mcg (Eltzschig 2003; Ngan Kee 2014; Whitty 2007).</p>\n    <p style=\"text-indent:0em;\">\n      <b>Combined spinal-epidural (CSE) technique for anesthesia for Cesarean delivery (off-label dosing [spinal component]): </b> 9 to 12 mg combined with fentanyl 15 mcg; in addition to fentanyl, may also include a longer-acting opioid (ie, morphine 100 to 150 <b>mcg</b>) for postoperative analgesia (Santos 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142943\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=bupivacaine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Bupivacaine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient. Do not use solutions containing preservatives for caudal or epidural block.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Caudal block, epidural block, local anesthesia:</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral or sympathetic nerve block:</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Retrobulbar anesthesia:</b> Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142928\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682358\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682359\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142906\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">P-Care M: 0.5%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ReadySharp Bupivacaine: 0.5%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Epidural, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% in NaCl 0.9% (250 mL); 0.25% in NaCl 0.9% (50 mL, 200 mL, 250 mL, 400 mL, 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Marcaine: 0.25% (50 mL); 0.5% (50 mL) [contains methylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sensorcaine: 0.25% (50 mL); 0.5% (50 mL) [contains methylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25% (30 mL [DSC], 50 mL); 0.5% (50 mL); 0.1% in NaCl 0.9% (500 mL); 0.125% in NaCl 0.9% (550 mL, 600 mL, 750 mL); 0.2% in NaCl 0.9% (500 mL); 0.25% in NaCl 0.9% (500 mL, 550 mL, 600 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Marcaine: 0.75% (10 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Marcaine Preservative Free: 0.25% (10 mL, 30 mL); 0.5% (10 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sensorcaine-MPF: 0.25% (10 mL, 30 mL); 0.5% (10 mL, 30 mL); 0.75% (10 mL, 30 mL) [methylparaben free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25% (10 mL, 20 mL [DSC], 30 mL); 0.5% (10 mL, 20 mL [DSC], 30 mL); 0.75% (10 mL, 20 mL [DSC], 30 mL); 0.1% in NaCl 0.9% (400 mL [DSC]); 0.25% in NaCl 0.9% (550 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intrathecal, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.75% [7.5 mg/mL] (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intrathecal, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bupivacaine Spinal: 0.75% [7.5 mg/mL] (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Marcaine Spinal: 0.75% [7.5 mg/mL] (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sensorcaine-MPF Spinal: 0.75% [7.5 mg/mL] (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Epidural, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25% in NaCl 0.9% (10 mL); 0.5% in NaCl 0.9% (10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142891\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142908\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Solutions containing preservatives should not be used for epidural or caudal blocks. The On-Q infusion pump is used to slowly administer local anesthetics (eg, bupivacaine, lidocaine, ropivacaine) to or around surgical wound sites and/or in close proximity to peripheral nerves for postoperative analgesia. When infused directly into the shoulder, destruction of articular cartilage (chondrolysis) has occurred. On-Q pumps should never be placed directly into any joint (see https://www.ismp.org/Newsletters/acutecare/archives/May09.asp).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142907\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Local or regional anesthesia; spinal anesthesia (0.75% in dextrose 8.25% injection); diagnostic and therapeutic procedures; obstetrical procedures (only 0.25% and 0.5% concentrations)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.25%: Local infiltration, peripheral nerve block, sympathetic block, caudal or epidural block</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.5%: Peripheral nerve block, caudal and epidural block</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.75% <b>(not for obstetrical anesthesia)</b>: Retrobulbar block, epidural block. <b>Note:</b> Reserve for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142970\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bupivacaine may be confused with mepivacaine, ropivacaine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Marcaine&reg; may be confused with Narcan&reg;</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142898\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Incidence of adverse reactions is difficult to define. Most effects are dose related, and are often due to accelerated absorption from the injection site, unintentional intravascular injection, or slow metabolic degradation. The development of any central nervous system symptoms may be an early indication of more significant toxicity (seizure).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Cardiovascular: Bradycardia, cardiac arrest, heart block, hypotension, palpitations, ventricular arrhythmia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Anxiety, dizziness, restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylactoid reaction, hypersensitivity reaction (urticaria, pruritus, angioedema) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Chondrolysis (continuous intra-articular administration), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Blurred vision, miosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Tinnitus </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Apnea, hypoventilation (usually associated with unintentional subarachnoid injection during high spinal anesthesia) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Seizure; usually associated with unintentional subarachnoid injection during high spinal anesthesia: cranial nerve palsy, fecal incontinence, headache, loss of anal sphincter control, loss of perineal sensation, paralysis, paresthesia, persistent anesthesia, septic meningitis, sexual disorder (loss of function), urinary incontinence</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142911\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to bupivacaine hydrochloride, amide-type local anesthetics, or any component of the formulation; obstetrical paracervical block anesthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Use as intravenous regional anesthesia (Bier block) is considered contraindicated per accepted clinical practice due to reports of cardiac arrest and death.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Obstetric paracervical block anesthesia; severe shock and in heart block where there is inflammation and/or sepsis near the proposed injection site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142895\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular effects: Bupivacaine-containing products have been associated with rare occurrences of arrhythmias, cardiac arrest, and death.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is <b>not</b> an approved use; chondrolysis (primarily shoulder joint) has occurred following infusion, with some patients requiring arthroplasty or shoulder replacement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest, especially when administered near the head or neck.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection or administration near the head or neck.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease including patients with hypotension or heart block. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acutely ill patients: Use with caution in acutely ill patients; dose reduction may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Debilitated patients: Use with caution in debilitated patients; dose reduction may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly; dose reduction may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Obstetrical anesthesia: <b> [US Boxed Warning]: The 0.75% concentration is not recommended for obstetrical anesthesia; cardiac arrest with difficult resuscitation or death has occurred. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Preservative-containing solutions: <b>Do not use solutions containing preservatives for caudal or epidural block.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sodium metabisulfite: May contain sodium metabisulfite; use caution in patients with asthma or a sulfite allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided. Intravenous regional anesthesia (Bier block) is not recommended; cardiac arrest and death have occurred with this method of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Test dose: A test dose is recommended prior to epidural administration (prior to initial dose) and all reinforcing doses with continuous catheter technique. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142957\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142900\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9169&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May increase the serum concentration of Bupivacaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine (Liposomal): Bupivacaine may enhance the adverse/toxic effect of Bupivacaine (Liposomal).  Management: Bupivacaine may be administered immediately before, or administered in the same admixture syringe as liposomal bupivacaine as long as the ratio of the milligram dose of bupivacaine to liposomal bupivacaine does not exceed 1:2.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142902\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2233562\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Bupivacaine crosses the placenta. Bupivacaine is approved for use at term in obstetrical anesthesia or analgesia. <b>[U.S. Boxed Warning]: The 0.75% is not recommended for obstetrical anesthesia.</b> Bupivacaine 0.75% solutions have been associated with cardiac arrest following epidural anesthesia in obstetrical patients and use of this concentration is not recommended for this purpose. Use in obstetrical paracervical block anesthesia is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20688278\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Bupivacaine is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142904\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs, state of consciousness; signs of CNS toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142894\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142910\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Anesthesia (route and dose dependent): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> Epidural: Up to 17 minutes to spread to T6 dermatome (Scott 1980)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> Infiltration: Fast (Barash 2009); Dental injection: 2 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> Spinal: Within 1 minute; maximum dermatome level achieved within 15 minutes in most cases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration (route and dose dependent): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epidural: 2 to 7.7 hours (Barash 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infiltration: 2 to 8 hours (Barash 2009); Dental injection: Up to 7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Spinal: 1.5 to 2.5 hours (Hadzic 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>:  Infants: 3.9 &plusmn; 2 L/kg; Children: 2.7 &plusmn; 0.2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 84% to 95% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; forms metabolite (pipecoloxylidine [PPX]) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination (age dependent): Neonates: 8.1 hours; Adults: 2.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Caudal, epidural, or peripheral nerve block: 30 to 45 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~6% unchanged)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Infants: 7.1 &plusmn; 3.2 mL/kg/minute; Children: 10 &plusmn; 0.7 mL/kg/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323027\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (ReadySharp Bupivacaine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (1): $247.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bupivacaine HCl (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (30 mL): $1.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (30 mL): $2.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (10 mL): $2.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bupivacaine HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (50 mL): $3.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (50 mL): $2.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bupivacaine HCl-NaCl (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1-0.9% (500 mL): $47.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125-0.9% (750 mL): $76.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2-0.9% (500 mL): $58.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25-0.9% (500 mL): $76.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.375-0.9% (100 mL): $32.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bupivacaine HCl-NaCl Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1-0.9% (250 mL): $18.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25-0.9% (250 mL): $28.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bupivacaine in Dextrose Intrathecal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75-8.25% (2 mL): $4.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Marcaine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (50 mL): $7.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (50 mL): $6.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (10 mL): $4.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Marcaine Preservative Free Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (10 mL): $3.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (10 mL): $4.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Marcaine Spinal Intrathecal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75-8.25% (2 mL): $5.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sensorcaine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (50 mL): $12.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (50 mL): $13.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sensorcaine-MPF Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (30 mL): $8.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (30 mL): $8.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (10 mL): $5.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sensorcaine-MPF Spinal Intrathecal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75-8.25% (2 mL): $4.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Bupivacaine HCl-NaCl Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5-0.9% (10 mL): $5.89</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038543\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anawin (BD);</li>\n      <li>Anekain (HR);</li>\n      <li>Bucain (DE, HU, ID);</li>\n      <li>Bucaine (AE, BH, CY, EG, HU, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Bunascan Spinal (ID);</li>\n      <li>Bupicaina (AR);</li>\n      <li>Bupican (LK, QA);</li>\n      <li>Bupican Heavy (LK);</li>\n      <li>Bupine (PK);</li>\n      <li>Bupinest S.P. (PE);</li>\n      <li>Bupinex (PY, UY);</li>\n      <li>Bupiright (PH);</li>\n      <li>Bupivacain Jenapharm (DE);</li>\n      <li>Bupivacain-RPR (DE);</li>\n      <li>Bupivacain-RPR CO!2 (DE);</li>\n      <li>Bupivacaine Aguettant (FR);</li>\n      <li>Bupivacaine B. Braun (FR);</li>\n      <li>Buvacaina (EC);</li>\n      <li>Buvacainas (CO);</li>\n      <li>Buvanest Spinal (ID);</li>\n      <li>Carbostesin (AT, CH, DE);</li>\n      <li>Chirocaina (VE);</li>\n      <li>Chlorhydrate de Bupivacaine Dakota (FR);</li>\n      <li>Dolanaest (DE);</li>\n      <li>Duracain (BD);</li>\n      <li>Duracaine (CL);</li>\n      <li>Indevus Spinal Heavy (ID);</li>\n      <li>Inibsacain (ES);</li>\n      <li>Kamacaine (IL);</li>\n      <li>Macaine (ZA);</li>\n      <li>Marcain (AU, DK, FI, GB, HN, HU, ID, IE, IS, IT, JP, LK, MY, NO, NZ, PT, RU, SE, SG, VN);</li>\n      <li>Marcain Spinal (BG, DK, EG, IS, LT, PL, SI, SK);</li>\n      <li>Marcaina (BR, GT, SV);</li>\n      <li>Marcaine (AE, BE, BG, BH, CY, CZ, EE, EG, FR, GR, HK, IL, IQ, IR, JO, KR, KW, LB, LT, LU, LV, LY, NL, OM, PH, PL, QA, SA, SI, SK, SY, TH, TR, TW, YE);</li>\n      <li>Marcaine Heavy (KR);</li>\n      <li>Marcaine Plain (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Marcaine Spinal Heavy (VN);</li>\n      <li>Markayin (UA);</li>\n      <li>Markayin Spinal (UA);</li>\n      <li>Nerkein (BD);</li>\n      <li>Picain (FI);</li>\n      <li>Pinacain (BD);</li>\n      <li>Pucaine (KR);</li>\n      <li>Recain (ID);</li>\n      <li>Regivell (PH);</li>\n      <li>Sanspen (PH);</li>\n      <li>Senpivac (PH);</li>\n      <li>Sensorcaine (IN, PH);</li>\n      <li>Sivicaine Heavy (BD);</li>\n      <li>Spica Spinal (ID);</li>\n      <li>Ultracaine (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Barash PG, Cullen BF, Stoelting RK, et al, eds. <i>Clinical Anesthesia</i>. 6th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dix SK, Rosner GF, Nayar M, et al, &ldquo;Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,&rdquo; <i>Crit Care Med</i>, 2011, 39(4):872-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/21263316/pubmed\" target=\"_blank\" id=\"21263316\">21263316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eltzschig HK, Lieberman ES, Camann WR. Regional anesthesia and analgesia for labor and delivery. <i>N Engl J Med</i>. 2003;348(4):319-332.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/12540646/pubmed\" target=\"_blank\" id=\"12540646\">12540646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foxall G, McCahon R, Lamb J, et al, &ldquo;Levobupivacaine-Induced Seizures and Cardiovascular Collapse Treated With Intralipid,&rdquo; <i>Anaesthesia</i>, 2007, 62(5):516-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/17448066/pubmed\" target=\"_blank\" id=\"17448066\">17448066</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hadzic A. Regional Anesthesia and Acute Pain Management. McGraw-Hill Education, 2001. http://accessanesthesiology.mhmedical.com/content.aspx?sectionid=39828160&amp;bookid=413&amp;jumpsectionID=39829430&amp;Resultclick=2&amp;q=bupivacaine.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehmann LJ and Pallares VS, &ldquo;Subdural Injection of a Local Anesthetic With Steroids: Complication of Epidural Anesthesia,&rdquo; <i>South Med J</i>, 1995, 88(4):467-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/7716603/pubmed\" target=\"_blank\" id=\"7716603\">7716603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Litz RJ, Popp M, Stehr SN, et al, &ldquo;Successful Resuscitation of a Patient With Ropivacaine-Induced Asystole After Axillary Plexus Block Using Lipid Infusion,&rdquo; <i>Anaesthesia</i>, 2006, 61(8):800-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/16867094/pubmed\" target=\"_blank\" id=\"16867094\">16867094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Long WB, Rosenblum S, and Grady IP, &ldquo;Successful Resuscitation of Bupivacaine-Induced Cardiac Arrest Using Cardiopulmonary Bypass,&rdquo; <i>Anesth Analg</i>, 1989, 69(3):403-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/2774240/pubmed\" target=\"_blank\" id=\"2774240\">2774240</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marcaine (bupivacaine) [prescribing information]. Lake Forest, IL: Hospira; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marcaine (bupivacaine) [product monograph]. Kirkland, Qu&eacute;bec, Canada: Pfizer Canada Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirtallo JM, Dasta JF, Kleinschmidt KC, et al, &ldquo;State of the Art Review: Intravenous Fat Emulsions: Current Applications, Safety Profile, and Clinical Implications,&rdquo; <i>Ann Pharmacother</i>, 2010, 44(4):688-700.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/20332339/pubmed\" target=\"_blank\" id=\"20332339\">20332339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moore PA and Hersh EV, &quot;Local Anesthetics: Pharmacology and Toxicity,&quot; <i>Dent Clin North Am</i>, 2010, 54(4):587-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/20831923/pubmed\" target=\"_blank\" id=\"20831923\">20831923</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mulroy MF, Hejtmanek MR. Prevention of local anesthetic systemic toxicity. <i>Reg Anesth Pain Med</i>. 2010;35(2):177-180.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/20216035/pubmed\" target=\"_blank\" id=\"20216035\">20216035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neal JM, Mulroy MF, and Weinberg GL, &ldquo;American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2012 Version,&rdquo; <i>Reg Anesth Pain Med</i>, 2012, 37(1):16-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/22189574/pubmed\" target=\"_blank\" id=\"22189574\">22189574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ngan Kee WD, Khaw KS, Ng FF, Ng KK, So R, Lee A. Synergistic interaction between fentanyl and bupivacaine given intrathecally for labor analgesia. <i>Anesthesiology</i>. 2014;120(5):1126-1136.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/24398818/pubmed\" target=\"_blank\" id=\"24398818\">24398818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenblatt MA, Abel M, Fischer GW, et al, &ldquo;Successful Use of a 20% Lipid Emulsion to Resuscitate a Patient After a Presumed Bupivacaine-Related Cardiac Arrest,&rdquo; <i>Anesthesiology</i>, 2006, 105(1):217-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/16810015/pubmed\" target=\"_blank\" id=\"16810015\">16810015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santos AC, Epstein J, Chaudhuri K, eds. <i>Obstetric Anesthesia</i>. New York, NY: McGraw-Hill Education, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scott DB, Lee A, Fagan D, et al, &ldquo;Acute Toxicity of Ropivacaine Compared With That of Bupivacaine,&rdquo; <i>Anesth Analg</i>, 1989, 69(5):563-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/2679230/pubmed\" target=\"_blank\" id=\"2679230\">2679230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sun KO, &ldquo;Convulsion Following Spinal Anaesthesia,&rdquo; <i>Anaesth Intensive Care</i>, 1995, 23(4):520-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/7485961/pubmed\" target=\"_blank\" id=\"7485961\">7485961</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tuominen MK, Pere P, and Rosenberg PH, &ldquo;Unintentional Arterial Catheterization and Bupivacaine Toxicity Associated With Continuous Interscalene Brachial Plexus Block,&rdquo; <i>Anesthesiology</i>, 1991, 75(2):356-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/1859023/pubmed\" target=\"_blank\" id=\"1859023\">1859023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whitty R, Goldszmidt E, Parkes RK, Carvalho JC. Determination of the ED95 for intrathecal plain bupivacaine combined with fentanyl in active labor.<i> Int J Obstet Anesth</i>. 2007;16(4):341-345.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/17697771/pubmed\" target=\"_blank\" id=\"17697771\">17697771</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9169 Version 169.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708636\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F142923\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F142924\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F142962\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F142927\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F142943\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F142928\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15682358\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682359\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F142906\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F142891\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F142908\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F142907\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F142970\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F142898\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F142911\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F142895\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F142957\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F142900\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F142902\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2233562\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20688278\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F142904\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F142894\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F142910\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323027\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038543\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9169|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bupivacaine-patient-drug-information\" class=\"drug drug_patient\">Bupivacaine: Patient drug information</a></li><li><a href=\"topic.htm?path=bupivacaine-pediatric-drug-information\" class=\"drug drug_pediatric\">Bupivacaine: Pediatric drug information</a></li></ul></div></div>","javascript":null}